2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchMeSH KeywordsAminoglycosidesAnti-Bacterial AgentsBotulinum Toxins, Type ADysphoniaDystoniaFemaleHumansLaryngeal MusclesPolytetrafluoroethyleneProspective StudiesTreatment OutcomeConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
2020
Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report
Kohli N, Blitzer A. Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report. Annals Of Otology Rhinology & Laryngology 2020, 129: 625-627. PMID: 31906695, DOI: 10.1177/0003489419898211.Peer-Reviewed Original ResearchMeSH KeywordsAdultBotulinum Toxins, Type AFacial MusclesHumansInjections, IntramuscularLaryngeal MusclesMaleNeuromuscular AgentsTourette SyndromeTreatment OutcomeConceptsYale Global Tic Severity ScaleTreatment of motorPhonic ticsCase reportTic Severity ScaleFacial mimetic musculatureOnabotulinum toxinFiberoptic visualizationBotulinum toxinThroat clearingTic disordersSeverity ScaleTic severityObjective decreaseMimetic musculaturePatientsTreatmentLevel VExperienced reductionsMusculatureToxinReportGruntingBoNTSeverity